Pap Smear Combined with HPV Testing: A Reasonable Tool for Women with High-grade Cervical Intraepithelial Neoplasia Treated by LEEP
| Autor: | Hong-Lin Song, Ling-Zhao Mo, Qing He, Fei Li, Jian-Li Wang, Zhang-Can Qiu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Neoplasm Residual Time Factors Electrosurgery Epidemiology medicine.medical_treatment Uterine Cervical Neoplasms Alphapapillomavirus Cervical intraepithelial neoplasia Gastroenterology Young Adult Predictive Value of Tests Internal medicine Cytology Genotype medicine Humans Retrospective Studies Vaginal Smears Gynecology business.industry Papillomavirus Infections Public Health Environmental and Occupational Health Retrospective cohort study Middle Aged Viral Load Uterine Cervical Dysplasia medicine.disease Oncology Predictive value of tests DNA Viral High Grade Cervical Intraepithelial Neoplasia Female Neoplasm Recurrence Local business Viral load Follow-Up Studies Papanicolaou Test |
| Zdroj: | Asian Pacific Journal of Cancer Prevention. 16:4297-4302 |
| ISSN: | 1513-7368 |
| DOI: | 10.7314/apjcp.2015.16.10.4297 |
| Popis: | Background: To evaluate HPV testing by Hybrid Capture II (HCII) in conjunction with cytology in detecting the residual/recurrence disease after treatment of high-grade cervical intraepithelial neoplasia (CIN II-III) with loop electrosurgical excision procedure (LEEP). Materials and Methods: A retrospective review of 158 patients with histologically confirmed CIN II-III who underwent LEEP between January 2011 and October 2012 was conducted. Post-treatment control was scheduled at the 3rd, 6th, 12th and 18th month. All patients were followed up by Pap smear and HR-HPV genotype and viral load testing. Results: Pre-treatment, HR-HPV DNA, was detected in all specimens of the patients. At follow-up, 25 patients were diagnosed as the residual/recurrent disease during the FU visit, among whom, 16 patients with positive margin: 13 patients (52%) with HR-HPV DNA+/ cytology+, 2 patients (8%) with HR-HPV DNA+/cytology-, 1 patient (4%) with cytology+/ HR-HPV DNA-; 9 patients with clean margin - 5 patients (55.6%) with HR-HPV DNA+/cytology+; 2 patients (22.2%) with HR- HPV DNA+/cytology-, 2 patients (22.2%) with cytology+/ HR-HPV DNA-. None of them persisting HR-HPV DNA-/cytology- with positive or negative margin was identified as the residual/recurrent disease. The majority of residual/recurrent disease was detected at the 12th and 18th month FU, and there was almost no difference in the sensitivity and negative predictive value (NPV) between at the 3rd month and the 6th month FU visits. 14 residual/recurrence disease (14/46:30.4%) had pre-treatment high viral load (>5 000 RUL/PC) and 11 (11/112, 9.8%) with pre-treatment low viral load, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|